Talphera (TLPH) Interest & Investment Income (2011 - 2026)
Talphera (TLPH) posted Interest & Investment Income of $172000.0 for Q2 2026, up 1.78% on a QoQ basis from $169000.0 in Q1 2026, and up 107.23% year-over-year from $83000.0 in Q2 2025.
Powered by 
Analysis
Talphera (TLPH) Interest & Investment Income (2011 - 2026) Analysis & Trends
Talphera has reported Interest & Investment Income for 16 years, with the latest figure at $172000.0 in Q2 2026.
- On a quarterly basis, Interest & Investment Income rose 107.23% year-over-year to $172000.0 in Q2 2026; TTM through Jun 2026 was $625000.0, a 52.44% increase from a year earlier, with the FY2025 full-year figure at $436000.0, down 35.79% from the prior year.
- Interest & Investment Income was $172000.0 for Q2 2026 at Talphera, up from $169000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $5.5 million in Q4 2023, with the low at $38000.0 in Q1 2022.
- Average Interest & Investment Income over 5 years is $491647.1, with a median of $155000.0 recorded in 2024.
- The sharpest annual moves came in 2023 and 2024: Interest & Investment Income soared 3908.03% in 2023, then sank 98.12% in 2024.
- Over 5 years, Interest & Investment Income stood at $137000.0 in 2022, then jumped by 3908.03% to $5.5 million in 2023, then tumbled by 98.12% to $103000.0 in 2024, then jumped by 97.09% to $203000.0 in 2025, then declined by 15.27% to $172000.0 in 2026.
- The last three Interest & Investment Income figures came in at $172000.0 (Q2 2026), $169000.0 (Q1 2026), and $203000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.58 Bn | 192.59 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.17 Bn | 176.99 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.59 Bn | 122.74 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 81.61 Bn | 73.61 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Argenx Se | 60.24 Bn | 55.05 Bn | 1.37 Bn | 48.00 Mn |
| 6 | Moderna | 54.29 Bn | 49.15 Bn | 52.00 Mn | 67.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.96 Bn | 29.65 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 31.94 Bn | 30.66 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.38 Bn | 29.38 Bn | 1.16 Mn | 36.92 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | 172,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 172,000.00 |
| Mar 31, 2026 | 169,000.00 |
| Dec 31, 2025 | 203,000.00 |
| Sep 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 83,000.00 |
| Mar 31, 2025 | 69,000.00 |
| Dec 31, 2024 | 103,000.00 |
| Sep 30, 2024 | 155,000.00 |
| Jun 30, 2024 | 201,000.00 |
| Mar 31, 2024 | 220,000.00 |
| Dec 31, 2023 | 5.49 Mn |
| Sep 30, 2023 | 187,000.00 |
| Jun 30, 2023 | 858,000.00 |
| Dec 31, 2022 | 137,000.00 |
| Sep 30, 2022 | 140,000.00 |
| Jun 30, 2022 | 51,000.00 |
| Mar 31, 2022 | 38,000.00 |
| Dec 31, 2021 | 32,000.00 |
| Sep 30, 2021 | 32,000.00 |
| Jun 30, 2021 | -16,000.00 |